Cambridge Cognition: Join us at SIRS 2018

Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th – 8th April 2018.

The 6th Biennial Schizophrenia International Research Society Conference (SIRS) is taking place in Florence from the 4th -8th April 2018.

 

Join us at the satellite meeting

For the first time the conference includes a day-long session on Cognition in Schizophrenia.

Our Director of Neuroscience, Dr Kiri Granger, recently hosted a webinar on overcoming methodological challenges in schizophrenia trials.

Join Dr Granger at the satellite session to hear the latest on improving pro-cognitive drug trials in schizophrenia.

 

Find us at the posters 

Meet our scientists at the posters to discuss:

  • Pro-cognitive drug trials in schizophrenia: how can we do them better?
  • Exploring participant-level trajectories of cognitive performance among patients with schizophrenia in a multi-national trial.
  • Clinical symptoms and not objective cognitive performance drive subjective cognitive complaints in patients with schizophrenia.
  • Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit?

Schedule a meeting with our experts  

Our Director of International Sales & Business Development, Dr Mark Miller-Holliday, will be available for one-to-one partnering meetings to discuss enhancing your pro-cognitive drug trial success in schizophrenia.

Dr Miller-Holliday will be joined by:

Jenny Barnett
Jenny Barnett, PhD
Chief Scientific Officer
Kiri Granger
Kiri Granger, PhD
Director of Neuroscience
Jack Cotter
Jack Cotter, PhD
Senior Scientist

 

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions